z-logo
open-access-imgOpen Access
Concomitant Primary Hyperparathyroidism in Patients with Multiple Myeloma: A Possible Link?
Author(s) -
Laura Notarfranchi,
Valentina Marchica,
Benedetta Dalla Palma,
Laura Pelagatti,
Jessica Burroughs-Garcìa,
M. Pedrazzoni,
Livia Ruffini,
Filomena Cetani,
Claudio Marcocci,
Nicola Giuliani
Publication year - 2020
Publication title -
acta haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.574
H-Index - 56
eISSN - 1421-9662
pISSN - 0001-5792
DOI - 10.1159/000509768
Subject(s) - concomitant , primary hyperparathyroidism , medicine , parathyroid hormone , multiple myeloma , hyperparathyroidism , endocrinology , bone disease , osteoporosis , gastroenterology , calcium
Hypercalcemia is a significant feature of patients with active multiple myeloma (MM) with extensive bone disease. Among the causes of non-neoplastic hypercalcemia, primary hyperparathyroidism (PHPT) is one of the most common, leading to osteoporosis and bone fractures. Interestingly, some preclinical data indicate that high secretion of parathyroid hormone (PTH) may have a negative impact on bone disease and MM progression. However, concomitant diagnosis of MM and PHPT has rarely been described. Here, we present 4 cases of patients with active MM and hypercalcemia with high or inappropriately normal PTH levels. Interestingly, CD138 + cells from these 4 MM patients lack PTH receptor 1 and PTH-related peptide expressions, indicating that PTH could have a paracrine rather than a direct pro-tumoral effect. Moreover, these cases suggest that the concomitant diagnosis of MM and PHTP may not be so rare and should be considered for the clinical management of MM patients with hypercalcemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom